Adicet Bio, Inc. (Nasdaq: ACET) has recently released groundbreaking clinical biomarker data from the Phase 1 GLEAN trial, showcasing the remarkable potential of their ADI-001 as a top-tier allogeneic cell therapy for autoimmune diseases. Led by Dr. Blake Aftab, Chief Scientific Officer, these findings will be presented at the 9th Annual CAR-TCR Summit in Boston, MA.
Successful B Cell Depletion
ADI-001 exhibited strong tissue trafficking, leading to a profound depletion of CD19+ B cells in secondary lymphoid tissues. This success in complete B cell removal holds significant promise for addressing various autoimmune diseases effectively.
Impressive Tissue Exposure
CAR T cell activation levels were notably high in lymph node biopsies, with impressive tissue exposure levels observed. This demonstrates the potential of ADI-001 to achieve superior exposure and activation compared to traditional therapies.
Forward Movement
With ongoing advancements, Adicet continues to progress their ADI-001 clinical program, focusing on conditions like lupus nephritis and systemic sclerosis. The company anticipates releasing initial clinical data in the first half of 2025.
Stay tuned for updates on this groundbreaking research! For more information, visit Adicet Bio's website.